ArticleCureus2025
Impact of Metabolic Surgery on Obesity Outcomes and Framingham Risk Score in Iranian Diabetic Patients: A Short- and Long-Term Follow-Up Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) and obesity are closely interlinked conditions, contributing significantly to health complications. Metabolic surgery (MS) could help to improve metabolic conditions, including diabetes, hypertension, and hyperlipidemia, which are significant risk factors for cardiovascular disease. This study aimed to evaluate the short-term and long-term effects of MS on obesity outcomes and the Framingham Risk Score (FRS) in Iranian diabetic patients. This multicenter, retrospective study included T2DM patients with body mass index (BMI) ≥ 30 kg/m² who underwent MS in Ahvaz, Iran, from 2019 to 2023. Of the 151 patients, 105 with a follow-up of at least one year were included. Among them, 29 patients (27.6%) had a long-term follow-up (four to five years). Anthropometric and biochemical parameters, comorbidities, and FRS were evaluated at baseline and at one-year and long-term follow-ups. One year postoperatively, there were significant reductions in weight, BMI, systolic and diastolic blood pressure, FRS, triglycerides, low-density lipoprotein (LDL), liver enzymes, fasting blood glucose, and hemoglobin A1c (HbA1c), with an increase in high-density lipoprotein (HDL) levels. The percentage of total weight loss (%TWL) and excess weight loss (%EWL) were 29.13 ± 8.42 and 71.03 ± 20.88, respectively. The median FRS decreased from 11.70 pre-surgery to 4.50 and 6.30 at one-year and long-term follow-ups (P<0.0001). Complete remission of T2DM, hypertension, and hyperlipidemia was achieved in 75.2%, 48.2%, and 35.1% of patients, respectively, and improvements were sustained throughout the follow-up period. The type of MS had no significant impact on changes in weight or BMI (P>0.05). Surgery-related side effects were observed in four cases (3.80%). MS is a safe and effective procedure for reducing obesity-related complications, including T2DM, hypertension, hyperlipidemia, and cardiovascular risk in both the short and long term. These findings highlight the promising potential of MS in managing diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.